Skip to main content Skip to navigation
Purified Rat Anti-Mouse Ly-6G
Purified Rat Anti-Mouse Ly-6G
Expression of Ly-6G on peripheral-blood leukocytes. C57BL/6 whole blood was stained with purified 1A8 mAb in the presence of Mouse Fc Blockª (purified anti-mouse CD16/CD32, Cat. No. 553141/553142), followed by FITC-conjugated anti-rat IgG2a mAb RG7/1.30 (Cat. No. 553896, Far and middle left panels, right panel), then PE-conjugated anti-mouse Ly-6G and Ly-6C mAb RB6-8C5 (Cat. No. 553128, far and middle right panels). Erythrocytes were lysed (PharmLyse™, Cat. No. 555899), non-viable leukocytes were excluded by staining with propidium iodide, and leukocyte subsets were distinguished by their light-scatter profiles. Far left panel displays the expression of Ly-6G on granulocytes filled histogram) and lymphocytes/monocytes (open histogram). Note that Ly-6G expression is almost exclusively on granulocytes. Middle left and far and middle right panels compare the staining patterns of mAbs 1A8 and RB6-8C5 on total blood leukocytes. It is evident that mAb 1A8 stains the RB6-8C5-bright population, corresponding to Ly-6G-expressing granulocytes; whereas, the RB6-8C5-dim population is 1A8-negative and corresponds to Ly-6C-expressing lymphocytes and monocytes. Flow cytometry was performed on a FACSCalibur™ (BDIS, San Jose, CA).
Expression of Ly-6G on peripheral-blood leukocytes. C57BL/6 whole blood was stained with purified 1A8 mAb in the presence of Mouse Fc Blockª (purified anti-mouse CD16/CD32, Cat. No. 553141/553142), followed by FITC-conjugated anti-rat IgG2a mAb RG7/1.30 (Cat. No. 553896, Far and middle left panels, right panel), then PE-conjugated anti-mouse Ly-6G and Ly-6C mAb RB6-8C5 (Cat. No. 553128, far and middle right panels). Erythrocytes were lysed (PharmLyse™, Cat. No. 555899), non-viable leukocytes were excluded by staining with propidium iodide, and leukocyte subsets were distinguished by their light-scatter profiles. Far left panel displays the expression of Ly-6G on granulocytes filled histogram) and lymphocytes/monocytes (open histogram). Note that Ly-6G expression is almost exclusively on granulocytes. Middle left and far and middle right panels compare the staining patterns of mAbs 1A8 and RB6-8C5 on total blood leukocytes. It is evident that mAb 1A8 stains the RB6-8C5-bright population, corresponding to Ly-6G-expressing granulocytes; whereas, the RB6-8C5-dim population is 1A8-negative and corresponds to Ly-6C-expressing lymphocytes and monocytes. Flow cytometry was performed on a FACSCalibur™ (BDIS, San Jose, CA).
Product Details
Down Arrow Up Arrow


BD Pharmingen™
Mouse (QC Testing)
Rat LEW, also known as Lewis IgG2a, κ
Ly-6G-transfected EL4J Cell Line
Flow cytometry (Routinely Tested), Immunohistochemistry-frozen, Immunohistochemistry-paraffin, Immunoprecipitation, Induction (Reported)
0.5 mg/ml
AB_394206
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4°C.

Recommended Assay Procedures

Recommended Assay Procedure:

For flow cytometry of leukocyte suspensions, we recommend the use of Mouse Fc Block™ (purified anti-mouse CD16/CD32 mAb 2.4G2, Cat. No. 553141/553142). If Mouse Fc Block™ is used, it is important that the second-step antibody does not react with the 2.4G2 mAb (rat IgG2b, κ); we recommend FITC-conjugated anti-rat IgG2a mAb RG7/1.30 (Cat. No. 553896). Other reported applications include immunoprecipitation, immunohistochemical staining (IHC) of paraffin-embedded and acetone fixed frozen sections, and induction of T-cell inhibitory signalling. For IHC, we recommend the use of purified RB6-8C5 mAb in our special formulation for immunohistochemistry, Cat. No. 550291.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
551459 Rev. 1
Antibody Details
Down Arrow Up Arrow
1A8

The 1A8 monoclonal antibody specifically binds to Ly-6G, a 21-25-kDa GPI-anchored protein. In the bone marrow, Ly6G is expressed on the majority of the largest cells, predominantly granulocytes, but not on lymphoid or erythroid cells.  In the periphery, it is expressed on granulocytes. The mAb RB6-8C5 recognizes both Ly-6G and Ly-6C and blocks the binding of mAb 1A8 to Ly-6G.

This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

551459 Rev. 1
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
551459 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (2)

  1. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993; 151(5):2399-2408. (Immunogen: Immunoprecipitation). View Reference
  2. Fleming TJ, Malek TR. Multiple glycosylphosphatidylinositol-anchored Ly-6 molecules and transmembrane Ly-6E mediate inhibition of IL-2 production. J Immunol. 1994; 153(5):1955-1962. (Clone-specific: Induction). View Reference
551459 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.